XETRA •
Healthcare •
Biotechnology •
Quote as of 05/04/2026 18:13
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeXETRA
Market Capitalization35,342 mln
Float132 mln
Earnings Date04/30/2026
EPS
1.83
Stretched
P / E
138
Highly speculative
Piotroski F-Score
7
/ 9
Strong
Beneish M-Score
-1.74
Likely manipulated
Relative Strength
21
/ 100
Significantly lagging
Debt / Equity
1.18
Elevated leverage
Business Description
Alnylam Pharmaceuticals is a Cambridge, Massachusetts-based biotech company founded in 2002 that uses RNA interference technology to create medicines that silence disease-causing genes. The company already sells several approved treatments for conditions such as rare hereditary diseases, high cholesterol, and hemophilia, while also running an extensive pipeline of experimental therapies targeting heart disease, neurological conditions, metabolic disorders, and certain cancers. Alnylam works alongside major pharmaceutical partners including Novartis, Roche, Sanofi, and Regeneron to advance its research and bring new treatments to patients around the world.
